home / stock / cprx / cprx news


CPRX News and Press, Catalyst Pharmaceuticals Inc. From 02/28/24

Stock Information

Company Name: Catalyst Pharmaceuticals Inc.
Stock Symbol: CPRX
Market: NASDAQ
Website: catalystpharma.com

Menu

CPRX CPRX Quote CPRX Short CPRX News CPRX Articles CPRX Message Board
Get CPRX Alerts

News, Short Squeeze, Breakout and More Instantly...

CPRX - Expected US Company Earnings on Wednesday, February 28th, 2024

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

CPRX - Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and d...

CPRX - Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality...

CPRX - Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients liv...

CPRX - (CPRX) Trading Report

2024-02-08 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CPRX - Biotech And Pharma Diversification Pays Off

2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...

CPRX - Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch

2024-01-22 19:45:34 ET Summary Catalyst Pharmaceuticals is a biopharmaceutical company specializing in treatments for rare neurological and epileptic disorders. The company's main products are Firdapse and Fycompa, which make up the majority of its revenue. The launch of Agamr...

CPRX - Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

2024-01-18 04:54:59 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a rec...

CPRX - Where are the Opportunities in (CPRX)

2024-01-17 19:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CPRX - Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

2024-01-17 14:13:32 ET Summary Catalyst Pharmaceuticals, Inc. has one approved product and another about to be launched, but its market cap is low at $1.7bn. The company is facing a major patent challenge and has high expenses with no major data catalysts or pipeline molecules. ...

Previous 10 Next 10